Treace Medical Concepts, Inc. revised revenue guidance for the year 2023. The company is updating its full-year 2023 revenue guidance to $182 million to $186 million, which represents approximately 28% to 31% growth over the Company?s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $191 million to $197 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.94 USD | -1.20% | +9.05% | -61.25% |
05-17 | North American Morning Briefing : The "Everything -2- | DJ |
05-16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.25% | 310M | |
+73.10% | 12.39B | |
-19.92% | 7.89B | |
+8.05% | 6.59B | |
+12.49% | 5.43B | |
+40.80% | 4.96B | |
-17.45% | 4.72B | |
-20.60% | 4.02B | |
-28.94% | 2.66B | |
+61.09% | 2.37B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023